Search Results

AbbVie announced that it has completed its acquisition of Landos Biopharma, Inc.

AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.

Landos Biopharma, Inc. today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.

Landos Biopharma, Inc. provided a business update and announced financial results for the quarter ended September 30, 2023.

The NIMML Institute (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for autoimmune diseases, today recognized its co-founders, Dr. Josep Bassaganya-Riera and Dr. Raquel Hontecillas, and scientific director Dr. Andrew Leber for their leadership in the discovery and development of NX-13 that enabled today’s acquisition of Landos Biopharma, Inc. (“Landos”) by AbbVie, Inc. (NYSE: ABBV) (“AbbVie”).

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced that six abstracts were accepted for poster presentation at the 19th Annual Congress of the European Crohn’s and Colitis Organisation.

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, President Trump issued multiple executive orders that concern the industry.

While layoffs slowed in the second half of 2024, biopharmas including Bayer, Bristol Myers Squibb and Johnson & Johnson cut hundreds or even thousands of employees over the course of the year.

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea for the slow, healthy recovery of the industry at large.